ERY-TAB (erythromycin)
ERY-TAB is a macrolide antibiotic used to manage a variety of bacterial infections, particularly those affecting the respiratory tract and skin. It helps patients with conditions such as whooping cough, diphtheria, and listeriosis, and it can also be used to prevent the spread of certain bacteria in infected individuals. This medication is typically prescribed when a bacterial cause is confirmed or strongly suspected to ensure the drug remains effective against resistant strains.
How ERY-TAB Works
This medication works by binding to the 50S ribosomal subunits of susceptible bacteria, which inhibits their ability to synthesize proteins. By blocking this essential process without affecting nucleic acid synthesis, the drug effectively stops the growth and spread of the infection.
Details
- Status
- Prescription
- First Approved
- 1982-03-29
- Routes
- ORAL
- Dosage Forms
- TABLET, DELAYED RELEASE
ERY-TAB Approval History
What ERY-TAB Treats
5 indicationsERY-TAB is approved for 5 conditions since its original approval in 1982. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Upper Respiratory Tract Infection
- Lower Respiratory Tract Infection
- Listeriosis
- Respiratory Tract Infection
- Skin Infection
ERY-TAB Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
Same target(s) AND same indication — head-to-head.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to ERY-TAB
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
25 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT07394725 | 130/IRV/SLMC/SWL | Ph 1 | completed | Unlocking New Avenues: Azithromycin Vs Erythromycin in Pre-term, Pre-mature Rupture of Membrane Management |
| NCT06396078 | 2024H0122 | Ph 4 | recruiting | Improvement of PPROM Management With Prophylactic Antimicrobial Therapy (iPROMPT) |
| NCT06948747 | D7260C00017 | Ph 1 | completed | A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants |
| NCT06273891 PRACET | INOVA-2023-58 23-08-WC-0198 | Ph 3 | recruiting | Erythromycin Versus Azithromycin for Preterm Prelabor Rupture of Membranes |
| NCT06917872 | 1397-0029 2024-515795-12-00, U1111-1310-2268 | Ph 1 | completed | A Study in Healthy People to Test Whether Erythromycin Influences the Amount of BI 1291583 in the Blood |
| NCT01556334 PEACE | PEACE Trial-1011004323 | Ph 3 | withdrawn | Erythromycin Versus Azithromycin in Preterm Premature Rupture of Membranes |
| NCT03024879 | MotilinAndFoodIntake | Ph 4 | enrolling by invitation | The Effect of Motilin on the Frequency and Amount of Food Intake |
| NCT06395610 | CLI-06001AA1-14 2023-507300-30-00 | Ph 1 | completed | Effect of Erythromycin on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers |
| NCT03060473 TREAT results posted | 16-0323 | Ph 3 | terminated | Treatment of ppROM With Erythromycin vs. Azithromycin Trial |
| NCT05995249 | TAK-279-1002 | Ph 1 | completed | A Study of the Interaction of TAK-279 With Substances That Have an Impact on Metabolism in Healthy Adults |
| NCT04714554 | MVT-601-054 | Ph 1 | completed | A Study of the Effects of Erythromycin on the Pharmacokinetics of Relugolix, Estradiol, and Norethindrone in Healthy Postmenopausal Women and on the Pharmacokinetics of Relugolix in Healthy Adult Men |
| NCT03480243 results posted | UP0057 2017-004694-13 | Ph 1 | completed | Study to Evaluate the Effect of Coadministered Erythromycin on the Pharmacokinetics and Safety of Padsevonil |
| NCT01342198 | A0081197 | Ph 1 | completed | An Investigation of the Effects of Erythromycin on the Pharmacokinetics of the Pregabalin Controlled Release Tablet |
| NCT02381080 | CR106609 PCI-32765LYM1003, 2015-000325-36 | Ph 1 | completed | Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy |
| NCT02212821 | Erythromycin_v6 | Ph 4 | completed | Brain Mechanisms Underlying the Effect of the Motilin Receptor Agonist Erythromycin on Hunger in Normal Weight Subjects |
| NCT01668498 | AIO-LQ-0110 2010-022938-85 | Ph 2 | completed | Comparison of Two Preemptive Treatment Strategies of Panitumumab Mediated Skin Toxicity and Assessment of QoL in Patient With Ras-wt Colorectal Cancer |
| NCT01379183 results posted | 10-004869 P01DK068055 | Ph 2, Ph 3 | completed | Using Magnetic Resonance (MR) to Understand the Effect of Erythromycin on Bowel Motility |
| NCT00827216 | NAC 06-225 Swissmedic 2008 DR 2321 | Ph 2 | completed | The Effect of Intravenous Erythromycin on Gastric Emptying in Non-fasted Patients Before Emergency Total Anesthesia |
| NCT01323582 AZI results posted | 645-2008 | Ph 2 | terminated | Comparison of Two Macrolides, Azithromycin and Erythromycin, for Symptomatic Treatment of Gastroparesis |
| NCT01946256 | ERC/2013/09/06 | Ph 2 | completed | Treatment of Antenatal Chlamydia Infection |
| NCT01478256 results posted | SAIRB-11-0007 | Ph 4 | completed | Comparative Study in the Efficacy of Topical Besifloxocin With Erythromycin for the Management of Acute Blepharitis |
| NCT01659619 | KC12MISI0164 | Ph 2 | completed | Effect of Erythromycin Before Endoscopy of Patients With Subtotal Gastrectomy (STG), High Risk of Gastric Stasis |
| NCT01323257 | CR018010 TMC435-TiDP16-C115 | Ph 1 | completed | TMC435-TiDP16-C115 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and Erythromycin and Between TMC435 and Darunavir/Ritonavir (DRV/r) |
| NCT01338441 iQTEST | 2010-022000-41 | Ph 1 | completed | Selections of Subjects With Important Changes in Their Cardiac Repolarization Parameters for the Procurement of Skin and Blood Samples |
| NCT01117376 | CT-88-01-36-1601 | Ph 2 | terminated | Methylnaltrexone vs Erythromycin for Facilitating Gastric Emptying Time in Critically Ill Patients |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
ERY-TAB FDA Label Details
Indications & Usage
FDA Label (PDF)ERY-TAB is indicated for the treatment of Upper Respiratory Tract Infection; Lower Respiratory Tract Infection; Listeriosis; Respiratory Tract Infection; Skin Infection.
Track ERY-TAB with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.